Literature DB >> 9815652

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

N M Navone1, M Olive, M Ozen, R Davis, P Troncoso, S M Tu, D Johnston, A Pollack, S Pathak, A C von Eschenbach, C J Logothetis.   

Abstract

Human prostate cancer cell lines are particularly difficult to establish, and most existing cell lines do not exhibit features commonly seen in human prostate cancer. Most available models either grow only in vivo as xenografts or are androgen insensitive and fail to express prostate-specific antigen (PSA). The lack of functionally relevant model systems of advanced prostate cancer has limited prostate cancer research and therapy development. Of 30 processed samples derived from patients with prostate cancer, we established two cell lines (MDA PCa 2a and MDA PCa 2b) that express PSA and androgen receptor, grow in vitro, and are androgen sensitive. Cells from these lines produced tumors in nude mice when injected either s. c. or orthotopically (intraprostatic). Both cell lines were established from a bone metastasis of a patient whose cancer was exhibiting androgen-independent growth. Although both were derived from two samples of the same specimen, they have different genetic features (as assessed by karyotype analysis) and different phenotypes (e.g., morphology and growth rate). It is likely that they are distinct clones isolated by the use of different culture procedures and reflect the genetic heterogeneity of the tumor. These new cell lines are the first available derived from a bone metastasis of an androgen-independent prostatic adenocarcinoma that grow both in vivo and in vitro and have retained PSA expression and androgen sensitivity. They therefore constitute important model systems to address critical questions related to the androgen-independent growth of human prostate cancer and to the complex process of bone metastasis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815652

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  78 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.

Authors:  Steven R Barthel; Jacyln D Gavino; Georg K Wiese; Jennifer M Jaynes; Javed Siddiqui; Charles J Dimitroff
Journal:  Glycobiology       Date:  2008-07-22       Impact factor: 4.313

3.  Macrophage cathepsin K promotes prostate tumor progression in bone.

Authors:  M K Herroon; E Rajagurubandara; D L Rudy; A Chalasani; A L Hardaway; I Podgorski
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

4.  Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.

Authors:  Y Li; Z Y Tang; S L Ye; Y K Liu; J Chen; Q Xue; J Chen; D M Gao; W H Bao
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

5.  Mouse models for studying prostate cancer bone metastasis.

Authors:  Jinlu Dai; Janine Hensel; Ning Wang; Marianna Kruithof-de Julio; Yusuke Shiozawa
Journal:  Bonekey Rep       Date:  2016-02-17

6.  Establishment and characterization of a pair of non-malignant and malignant tumor derived cell lines from an African American prostate cancer patient.

Authors:  Shaniece Theodore; Starlette Sharp; Jianjun Zhou; Timothy Turner; Hongzhen Li; Jun Miki; Youngmi Ji; Vyomesh Patel; Clayton Yates; Johng S Rhim
Journal:  Int J Oncol       Date:  2010-12       Impact factor: 5.650

7.  Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H.

Authors:  Dennis J van de Wijngaart; Michel Molier; Scott J Lusher; Remko Hersmus; Guido Jenster; Jan Trapman; Hendrikus J Dubbink
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

8.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 9.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

10.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.